Pharma consulting: 医療用医薬品のコンサルティング
04 Nov 2019
You’ve probably noticed that biosimilars are the growth engine in global medicine spending right now. You’re not alone. With biologics accounting for 20-22% of total pharmaceutical spending already and looking to grow to $320 bn in the US alone by 2023, more and more companies and looking to compete in this arena. Informa’s Biosimilars Insights and Analysis Service can bring you the market intelligence and insights to inform your decisions and help ensure you’re not missing out on opportunities.